Last reviewed · How we verify
Ga-68 PSMA-HBED-CC PET
At a glance
| Generic name | Ga-68 PSMA-HBED-CC PET |
|---|---|
| Also known as | Gallium-68 PSMA-HBED-CC PET scan |
| Sponsor | Michael Graham PhD, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (PHASE2)
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) (PHASE2)
- Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy (EARLY_PHASE1)
- 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer (PHASE2)
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma (PHASE2)
- Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study (PHASE2)
- An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ga-68 PSMA-HBED-CC PET CI brief — competitive landscape report
- Ga-68 PSMA-HBED-CC PET updates RSS · CI watch RSS
- Michael Graham PhD, MD portfolio CI